tetano
Editor, Senior Moderator
Vaccine. 2012 Mar 21. [Epub ahead of print]
Health and economic impact of the seasonal influenza vaccination programme in England.
Baguelin M, Jit M, Miller E, Edmunds WJ.
Source
Health Protection Agency, United Kingdom; Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, United Kingdom.
Abstract
BACKGROUND:
The seasonal influenza vaccination programme in England targets individuals over 65years old and in clinical risk groups.
METHODS:
A model of influenza transmission and disease was fitted to weekly primary care consultations due to influenza in a typical pre-pandemic season (2006/2007). Different scenarios were constructed about influenza severity and how well vaccines match circulating strains to assess the impact and cost-effectiveness of the current vaccination programme.
RESULTS:
A well-matched vaccine may reduce the incidence of laboratory-confirmed influenza illness from 8.2% (95% range 4.3-13%) to 5.9% (95% range 2.9-9.7%), with 56-73% of this due to indirect protection. The programme is likely to be cost-effective unless both low severity and poor matching is assumed.
CONCLUSION:
The current seasonal influenza vaccination programme appears to substantially reduce disease burden and provides good value for money.
Copyright © 2012. Published by Elsevier Ltd.
PMID:
22446636
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22446636
Health and economic impact of the seasonal influenza vaccination programme in England.
Baguelin M, Jit M, Miller E, Edmunds WJ.
Source
Health Protection Agency, United Kingdom; Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, United Kingdom.
Abstract
BACKGROUND:
The seasonal influenza vaccination programme in England targets individuals over 65years old and in clinical risk groups.
METHODS:
A model of influenza transmission and disease was fitted to weekly primary care consultations due to influenza in a typical pre-pandemic season (2006/2007). Different scenarios were constructed about influenza severity and how well vaccines match circulating strains to assess the impact and cost-effectiveness of the current vaccination programme.
RESULTS:
A well-matched vaccine may reduce the incidence of laboratory-confirmed influenza illness from 8.2% (95% range 4.3-13%) to 5.9% (95% range 2.9-9.7%), with 56-73% of this due to indirect protection. The programme is likely to be cost-effective unless both low severity and poor matching is assumed.
CONCLUSION:
The current seasonal influenza vaccination programme appears to substantially reduce disease burden and provides good value for money.
Copyright © 2012. Published by Elsevier Ltd.
PMID:
22446636
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22446636